Jordi Remon/X
Mar 28, 2025, 14:31
Jordi Remon: Adagrasib and pembrolizumab show impressive mPFS in KRAS G12C mutant NSCLC
Jordi Remon, Thoracic Oncologist at CIOCC Barcelona, shared a post on X:
“Adagrasib 400 mg and Pembrolizumab impressive mPFS in KRAS G12C mutant NSCLC and PDL1 >50% and good safety.
Better than IO or CT and IO alone. Good chem-free strategy for patients.
Await the ph3 trial.”
More posts featuring Jordi Remon.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 12:48
Apr 1, 2025, 12:16
Apr 1, 2025, 12:13
Apr 1, 2025, 12:07
Apr 1, 2025, 11:53